Arrowhead Pharmaceuticals Ownership | Who Owns Arrowhead Pharmaceuticals?
Arrowhead Pharmaceuticals Ownership Summary
Arrowhead Pharmaceuticals is owned by 79.91% institutional investors, 4.71% insiders, and 15.38% retail investors. Blackrock funding, inc. /de is the largest institutional shareholder, holding 13.51% of ARWR shares. iShares Core S&P Small-Cap ETF is the top mutual fund, with 6.28% of its assets in Arrowhead Pharmaceuticals shares.
ARWR Ownership Benchmark
Type | Name | % Inst | % Insiders | % Retail |
---|---|---|---|---|
Stock | Arrowhead Pharmaceuticals | 79.91% | 4.71% | 15.38% |
Sector | Healthcare Stocks | 57.43% | 9.41% | 33.16% |
Industry | Biotech Stocks | 69.02% | 8.92% | 22.06% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
Holder | Shares | % Holding | Value |
---|---|---|---|
Blackrock funding, inc. /de | 16.18M | 13.51% | $304.15M |
Blackrock | 15.68M | 12.72% | $407.61M |
Vanguard group | 12.18M | 10.17% | $229.06M |
Avoro capital advisors | 11.11M | 9.28% | $208.89M |
State street | 6.02M | 4.82% | $113.11M |
Slate path capital lp | 5.23M | 4.37% | $98.36M |
Fmr | 5.10M | 4.26% | $95.90M |
Geode capital management | 2.95M | 2.47% | $55.57M |
Siren | 2.90M | 2.42% | $54.55M |
T. rowe price investment management | 2.51M | 2.09% | $47.14M |
Top Institutional Shareholders by % of Total Assets
Holder | Shares | % Assets | Value |
---|---|---|---|
Aquilo capital management | 707.59K | 20.06% | $13.30M |
Western financial corp/ca | 820.24K | 8.47% | $15.42M |
Avoro capital advisors | 11.11M | 2.95% | $208.89M |
Siren | 2.90M | 2.41% | $54.55M |
Hound partners | 325.52K | 2.35% | $6.12M |
Slate path capital lp | 5.23M | 1.78% | $98.36M |
Privium fund management b.v. | 380.59K | 1.62% | $7.16M |
M28 capital management lp | 67.40K | 1.24% | $1.27M |
Altium capital management lp | 230.26K | 1.23% | $4.33M |
Johnson & johnson | 247.60K | 1.21% | $4.65M |
Top Buyers
Holder | Shares | % Assets | Change |
---|---|---|---|
Avoro capital advisors | 11.11M | 2.95% | 2.22M |
Norges bank | 2.05M | 0.01% | 2.05M |
Ubs group | 1.31M | 0.00% | 863.82K |
Morgan stanley | 1.82M | 0.00% | 679.41K |
Farallon capital management | 628.80K | 0.06% | 628.80K |
Top Sellers
Holder | Shares | % Assets | Change |
---|---|---|---|
T. rowe price investment management | 2.51M | 0.03% | -1.07M |
Fmr | 5.10M | 0.01% | -966.49K |
Rokos capital management llp | - | - | -939.98K |
Orbimed advisors | - | - | -739.65K |
E. ohman j:or asset management ab | - | - | -714.21K |
New Positions
Holder | Shares | % Assets | Change | Value |
---|---|---|---|---|
Norges bank | 2.05M | 0.01% | 2.05M | $38.62M |
Farallon capital management | 628.80K | 0.06% | 628.80K | $11.82M |
Integral health asset management | 275.00K | 0.44% | 275.00K | $5.17M |
Wealthfront advisers | 109.57K | 0.01% | 109.57K | $2.73M |
Marshall wace, llp | 86.63K | 0.00% | 86.63K | $1.63M |
Sold Out
Holder | Change |
---|---|
Toronto dominion bank | -3.00 |
Financial gravity asset management | -4.00 |
Innealta capital | -11.00 |
Riggs asset managment | -14.00 |
Bell investment advisors | -19.00 |
Institutional Ownership Trends
Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
---|---|---|---|---|---|---|---|---|---|---|
Dec 31, 2024 | 285 | 1.42% | 99,767,650 | 4.15% | 79 | 1.25% | 133 | 7.26% | 88 | -3.30% |
Sep 30, 2024 | 278 | -1.77% | 95,591,794 | -2.21% | 76 | 1.22% | 124 | -8.15% | 89 | 7.23% |
Jun 30, 2024 | 282 | -1.40% | 97,756,300 | 2.92% | 79 | 1.34% | 135 | -7.53% | 82 | 7.89% |
Mar 31, 2024 | 286 | 1.06% | 94,985,786 | 22.73% | 77 | 1.48% | 146 | 18.70% | 76 | -19.15% |
Dec 31, 2023 | 283 | 9.69% | 77,395,477 | 5.41% | 72 | 1.54% | 123 | 7.89% | 94 | - |
Top Mutual Funds Shareholders
Holder | Shares | % Holding | Change |
---|---|---|---|
iShares Core S&P Small-Cap ETF | 7.92M | 6.28% | 4.30K |
iShares Core S&P Mid-Cap ETF | 4.05M | 3.25% | 13.43K |
Vanguard Total Stock Mkt Idx Inv | 3.70M | 2.96% | 36.42K |
iShares Russell 2000 ETF | 3.10M | 2.46% | -60.76K |
Vanguard Small Cap Index | 3.02M | 2.41% | 5.38K |
Vanguard Institutional Extnd Mkt Idx Tr | 1.89M | 1.51% | 519.00 |
Vanguard Small Cap Growth Index Inv | 1.71M | 1.36% | -4.62K |
SPDR® S&P Biotech ETF | 1.45M | 1.15% | 10.96K |
Fidelity Growth Compy Commingled Pl S | 1.41M | 1.13% | 47.16K |
Fidelity Growth Compy Commingled Pl O | 1.21M | 0.98% | 127.90K |
Recent Insider Transactions
Date | Name | Role | Activity | Value |
---|---|---|---|---|
Mar 03, 2025 | Anzalone Christopher Richard | Chief Executive Officer | Sell | $3.01M |
Mar 04, 2025 | Anzalone Christopher Richard | Chief Executive Officer | Sell | $2.27M |
Jan 23, 2025 | OLUKOTUN ADEOYE Y | - | Sell | $20.14K |
Jan 06, 2025 | Hamilton James C | Chief Discovery/Trans Medicine | Sell | $220.63K |
Jan 06, 2025 | Hamilton James C | Chief Discovery/Trans Medicine | Sell | $428.20K |
Insider Transactions Trends
Date | Buy | Sell |
---|---|---|
2025 Q1 | - | 13 |
2024 Q4 | - | 10 |
2024 Q3 | - | 1 |
2024 Q2 | - | 2 |
2024 Q1 | 3 | 37 |
ARWR Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools